CSL Limited (ASX: CSL)
Australia
· Delayed Price · Currency is AUD
273.72
-0.58 (-0.21%)
Nov 21, 2024, 4:10 PM AEST
CSL Limited Revenue
In the fiscal year ending June 30, 2024, CSL Limited had annual revenue of $14.80B USD with 11.19% growth. CSL Limited had revenue of $6.75B in the half year ending June 30, 2024, with 49.24% growth.
Revenue
$14.80B
Revenue Growth
+11.19%
P/S Ratio
5.96
Revenue / Employee
$452.63K
Employees
32,698
Market Cap
132.54B AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 14.80B | 1.49B | 11.19% |
Jun 30, 2023 | 13.31B | 2.75B | 26.02% |
Jun 30, 2022 | 10.56B | 252.00M | 2.44% |
Jun 30, 2021 | 10.31B | 1.16B | 12.67% |
Jun 30, 2020 | 9.15B | 612.20M | 7.17% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ResMed Inc. | 6.93B |
Pro Medicus Limited | 161.50M |
Fisher & Paykel Healthcare Corporation Limited | 1.60B |
Cochlear Limited | 2.24B |
Sonic Healthcare Limited | 8.97B |
Ramsay Health Care Limited | 16.66B |
Telix Pharmaceuticals Limited | 645.68M |
Clarity Pharmaceuticals Ltd | 11.51M |
CSL Limited News
- 4 weeks ago - New Data Presented at IDWeek 2024 Show Adjuvanted and High-Dose Influenza Vaccines are Comparable in Protecting Adults 65 Years of Age and Older Against Seasonal Influenza - PRNewsWire
- 5 weeks ago - CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy - PRNewsWire
- 5 weeks ago - CSL Seqirus Presents Data at IDWeek 2024 Highlighting the Urgent Need to Increase Influenza Vaccination Rates and the Benefits of Cell-Based Influenza Vaccines - PRNewsWire
- 6 weeks ago - GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report - Benzinga
- 6 weeks ago - CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian Influenza - PRNewsWire
- 6 weeks ago - Sanofi, GSK, CSL Tapped to Expand US Bird Flu Vaccine Supply - BNN Bloomberg
- 7 weeks ago - CSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza Vaccinations - PRNewsWire
- 7 weeks ago - Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination - PRNewsWire